Chenguang Biotech has released its 2026 interim report, showing net profit attributable to the parent company of 179 million yuan, a decrease of 16.95% compared with the same period last year. Total operating revenue was 3.159 billion yuan, down 13.63% year-on-year. Net cash inflow from operating activities was 1.218 billion yuan, down 33.43% year-on-year. The latest asset-liability ratio was 64.06%, gross margin was 13.46%, return on equity was 5.25%, and diluted earnings per share was 0.37 yuan.
Chenguang Biotech GroupNet profit down 16.95% year-on-year in interim report.